Randomized, Open-Label Study to Evaluate the Influence on the Ovarian Activity, and the Cervix Score Over Two Treatment Cycles of 4.0 mg Drospirenone Daily for 24 Days as Compared to 0.075 mg Desogestrel Daily for 28 Days in 60 Healthy, Young Females.
Phase of Trial: Phase II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Drospirenone (Primary) ; Desogestrel
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Leon Farma
- 24 Sep 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 23 Feb 2012 New trial record